Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss
Xencor earnings event and what it might mean for the stock
Xencor (XNCR) shares are in focus after second quarter results on 5 August 2026 showed a narrower quarterly net loss alongside a larger loss over the first half of the year.
See our latest analysis for Xencor.
The earnings update appears to have reinforced positive sentiment around Xencor, with a 36.2% 1 month share price return and a very large 1 year total shareholder return, even though the 3 and 5 year total shareholder returns remain negative.
If Xencor’s sharp move has caught your attention, this can be a useful moment to widen your watchlist with other healthcare AI opportunities through the Simply Wall St screener for 43 healthcare AI stocks
After a 36.2% jump in a month and a very large 1 year return, Xencor’s valuation now needs a closer look. Do the current risks and ongoing losses still leave sufficient potential reward for new buyers?
Most Popular Narrative: 24.3% Undervalued
The most followed narrative on Xencor compares a fair value of $28.50 to the last close at $21.58. It frames today’s price as leaving a meaningful gap to that estimate and ties this to a specific view of the pipeline and future earnings profile.
The company's next-generation engineering (e.g., bispecific TL1A x IL-23 antibody) leverages advances in immunology and personalized medicine, allowing Xencor to address complex disease pathways and capitalize on the industry trend towards highly tailored biologic therapies, thus supporting pipeline expansion and long-term top-line growth.
Want to see how this TL1A story turns into a $28.50 fair value? The narrative leans heavily on projected revenue compounding, margin lift and a rich future earnings multiple.
The overarching conclusion from that framework is clear. Fair value is anchored at $28.50 per share, which is higher than Xencor’s recent close at $21.58, and assumes a required return of 7.39% applied to those future cash flows and earnings estimates.
Result: Fair Value of $28.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Xencor’s story can change quickly if crowded TL1A competition erodes future market share or if trial delays push key clinical readouts further out.
Find out about the key risks to this Xencor narrative.
Another view on Xencor’s valuation
The first framework presents Xencor as 24.3% undervalued relative to a $28.50 fair value. A simpler cross check using its P/S ratio suggests a very different picture. At 15.3x sales, the stock trades above the US Biotechs average of 11.4x and far above a fair ratio of 0.6x, which indicates meaningful valuation risk if sentiment cools.
That gap raises a key question for investors: Is Xencor’s pipeline and revenue potential strong enough to keep the market comfortable with such a rich sales multiple, or is this where expectations have started to run ahead of fundamentals?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals around Xencor’s valuation and sentiment, this is a good time to look through the underlying data yourself and decide how you feel about the balance of risk and reward. To help frame that view, take a closer look at the 1 key reward and 1 important warning sign
Looking for more Xencor investment ideas?
If Xencor is on your radar after these earnings, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could round out your watchlist.
- Scan for potential mispriced opportunities and compare them with Xencor by checking the 51 high quality undervalued stocks.
- Strengthen your focus on financial resilience and see which companies pair solid cash positions with disciplined balance sheets through the solid balance sheet and fundamentals stocks screener (48 results).
- Get ahead of the crowd by finding quality businesses that the market has not fully embraced yet using the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com